Northwest Biotherapeutics
Bethesda
About Northwest Biotherapeutics
Northwest Biotherapeutics is a development stage biotechnology company focused on discovering, developing and commercializing immunotherapy products that generate and enhance immune system responses to treat cancer. The Company operates in the United States and is incorporated in Delaware, USA. Currently approved cancer treatments are frequently ineffective, can cause undesirable side effects and provide marginal clinical benefits. The Company’s approach in developing cancer therapies utilizes its expertise in the biology of dendritic cells, which are a type of white blood cell that activate the immune system. The Company’s cancer therapies have been demonstrated in clinical trials to significantly extend both time to recurrence and survival, whilst providing a superior quality of life with no debilitating side effects when compared with current therapies.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $174.4M
- Funding stage: IPO
- Last round: Post-IPO Debt (Dec 2024)
- Ticker: otcqb:NWBO
- Website: nwbio.com
- Phone: +1 240 497 9024
Industries & Categories
Biotechnology, Health Care, Medical, Medical Device, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/northwest-biotherapeutics-77468 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.